Rayoqta (abicipar pegol): Withdrawal of the marketing authorisation application for use in wet age- related macular degeneration

In its letter notifying the Agency of the withdrawal of the application, the company stated that it withdrew its application because the concerns raised by the EMA could not be resolved within the available time frame.


European Medicines Agency